DUBLIN – (BUSINESS WIRE) – The “Indian Diabetes Care Market, By Product Type (Diabetes Drugs And Diabetics), By Type Of Diabetes (Type 1, Type 2 And Gestational Diabetes), By End User (Hospital, Home Clinic, Home Care) By Region, The Report” Competition, Forecast and Opportunities, FY2027 “was added ResearchAndMarkets.com Offer.
The Indian diabetes care market was valued at $ 1,530.3M in FY 2020 and is expected to grow at a CAGR of 7.94% to $ 2,408.39M in FY 2026.
The Indian diabetes care market is experiencing steady growth due to the increasing geriatric population, increasing diabetic population and the adoption of an unhealthy lifestyle that leads to obesity and continues to increase the diabetic population. In addition, factors such as the advancement of technology and the rising cost of living are continuously fueling the diabetes care market in India.
The Diabetes Care Market is segmented on the basis of the Diabetes Type, Product Type, End User, Region, and Company. Depending on the product type, the market can be divided into diabetes drugs and diabetes care devices.
Among these, the diabetes drug segment is expected to dominate the market during the forecast period as it is widely used for all types of diabetes. Based on the type of diabetes, the market can be divided into type 1 diabetes, type 2 diabetes and gestational diabetes. Here the most common type of diabetes is Type 1.
In addition, the glucose monitors segment is expected to show the highest growth due to increasing cases of diabetics. The self-monitoring devices still dominate the market because they are relatively easy to use and cheaper.
Novo Nordisk India Private Limited, Sanofi India Limited and Eli Lilly India Pvt. Ltd. Ltd., Roche Diagnostics India Pvt Ltd., Abbott India Limited, Becton Dickinson Private Limited, Johnson & Johnson Private Limited, India Medtronic Pvt. Ltd. Ltd., Ypsomed India Private Ltd. and Novartis India Ltd are some of the companies operating in the Indian diabetes care market.
Main target group:
-
Manufacturers, dealers and end users
-
Market research and consulting company
-
Government agencies such as regulators and policy makers.
-
Organizations, forums and alliances related to diabetes care.
Years considered for this report:
-
Historic years: FY2016-FY2019
-
Base year: FY2020
-
Estimated year: FY2021
-
Forecast period: FY2022-FY2026
Main topics covered:
1. Product of Interest Introduction: Diabetes Care Market
2. Research methodology
3. Impact of COVID-19 on India’s Diabetes Care Market
4. Summary
5. Voice of the customer / customer insights
6. Diabetes Care Market Outlook in India
6.1. Market size & forecast
6.1.1. By value
6.2. Market share and forecast
6.2.1. By product type (diabetes medication vs. diabetes care devices)
6.2.2. By type of diabetes (type 1 diabetes, type 2 diabetes, gestational diabetes)
6.2.3. By end user (home care settings, hospitals, clinics)
6.2.4. By region (north, south, east, west)
6.2.5. By company
6.3. Product market card
7. Diabetes Device Market Outlook in India
7.1. Market size & forecast
7.1.1. By value
7.2. Market share and forecast
7.2.1. By product type (self-monitoring glucose monitors and continuous glucose monitors)
7.2.2. According to the type of diabetes
7.2.3. According to end user
8. Diabetes Drugs Market Outlook in India
8.1. Market size & forecast
8.1.1. By value
8.2. Market share and forecast
8.2.1. By product type (insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists), others (sodium-glucose co-transporter-2 (SGLT2) inhibitors, biguanides , Sulfonylureas))
8.2.2. According to the type of diabetes
8.2.3. According to end user
9. Market dynamics
9.1. Drivers / possibilities
9.2. Challenges / Limitations
10. Market trends and developments
11. Political and regulatory landscape
12. Economic profile of India
13. Competitive landscape
13.1. Company Profiles (Top 10 Companies, Including Diabetes Care Devices and Diabetes Drugs Market)
13.1.1. Novo Nordisk India Private Limited
13.1.2. Sanofi India Limited
13.1.3. Eli Lilly India Pvt. GmbH.
13.1.4. Roche Diagnostics India Pvt Ltd.
13.1.5. Abbott India Limited
13.1.6. Becton Dickinson Private Limited
13.1.7. Johnson & Johnson Private Limited
13.1.8. India Medtronic Pvt. GmbH.
13.1.9. Ypsomed India Private Ltd.
13.1.10. Novartis India Ltd.
14. Strategic Recommendations
Please visit https://www.researchandmarkets.com/r/410qj5 for more information on this report
